Research Contributions & Academic Work

Clinical excellence and scientific inquiry are inseparable in modern hematology-oncology. Dr. Kazi maintains an active research portfolio that bridges laboratory discoveries with bedside applications, focusing on next-generation cellular therapies, therapeutic optimization in blood malignancies, and improved management strategies for complex hematologic conditions. His published work in leading medical journals and involvement in collaborative research networks contribute to the expanding knowledge base that shapes contemporary blood cancer treatment and informs evidence-based clinical decision-making.

  1. Borah P, Kazi BS et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021;87:102525.
  2. Kazi BS. An interesting case of Langerhans cell histiocytosis. J Hematol Allied Sci. 2021;1:122–3.
  3. Kazi BS, et al. Pyruvate kinase deficiency case report. J Hematol Allied Sci. 2022;2:99–100.
  4. Kazi BS, Chakrapani A. ASH image: Hemophagocytosis. Published: 04/02/2024.
  5. Kazi BS, et al. Cold agglutinin syndrome from Mycoplasma pneumoniae. J Hematol Allied Sci. 2024;4:46–7.
  6. Bilal K, et al. EBV-induced Warm AIHA. Turk J Haematol. Published: June 28, 2024.
  7. Kazi B, Chakrapani A. Flame cells in IgA Myeloma. Indian J Hematol Blood Transfus. 2024. https://doi.org/10.1007/s12288-024-01819-6
  8. Kazi BS, Chakrapani A. Anaplastic Multiple Myeloma (ASH image). Published: 18/07/2024.
  9. Kazi BS, Shinde SV. Microfilaria in buffy coat (ASH image). Published: 22/07/2024.
  10. Rumani I, et al. Clinicopathological response post-NACT in LABC. J Curr Oncol Trends. 2024;1:54–62.
  11. Kazi B, et al. Eosinophilia masking splenic microfilariasis. Turk J Haematol. 2024;41(4):279–80.
  12. Kazi B, et al. Olanzapine-induced hypertriglyceridemia in cancer care. Curr Probl Cancer: Case Rep. 2024. https://doi.org/10.1016/j.cpccr.2024.100345.
  13. Kazi B, Adallah AO, Patil V, Tembhare P, Rumani I, Kazi MNC. Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure. Turk J Haematol. Published online July 28, 2025. doi:10.4274/tjh.galenos.2025.2025.0216.
  14. Vairamoorthy N, Kazi B, Patil V. Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. N Engl J Med. 2025;393(6):619-620. doi:10.1056/NEJMc2507794